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Objectives: Hypertension is a common chronic disease and risk factor for many 
other conditions. Despite effective treatments, few patients achieve recommended 
blood pressure targets. Among the variables related with poor antihypertensive 
outcomes, patient adherence appears to be especially influential. Adherence 
assessment should fit seamlessly into the clinical encounter, which requires sim-
ple methods. We evaluated whether adherence assessments through a single-item 
query and a visual analogue scale (VAS) are independent predictors of controlled 
systolic (SBP), diastolic (DBP), and combined systolic/diastolic (SBP/DBP) blood pres-
sure (BP). MethOds: Pooled analysis of 17,516 patients treated with valsartan as 
second-line therapy from seven Belgian studies. Adherence was assessed at baseline 
and 90 days using two methods: a single query derived from the Basel Assessment 
of Adherence Scale (“Do you recall not having taken your medication sometime in 
the past four weeks?”) and a physician-rated VAS (0-100 range). Logistic regression 
was used to model BP control as a function of these two measures. Controlled 
BP was defined as < 140mm/90mmHg (< 130/80mmHg for diabetics). Results: BP 
control rates at 90 days were 39.3% for SBP, 59.4% for DBP, and 33.8% for SBP/DBP. 
79% of patients identified as adherent under the single query reached BP control, 
with odds ratios of 0.66 (95%CI= 0.62-0.71, p< 0.001) for SBP, 0.68 (95%CI= 0.63-0.73, 
p< 0.001) for DBP, and 0.64 (95%CI= 0.59-0.70, p< 0.001) for SBP/DBP. Of those patients 
with a physician-rated VAS adherence score of 80 or more, 81% reached BP control, 
with odds ratios of 0.93 (95%CI= 0.86-1.00, p< 0.001) for SBP, 0.79 (95%CI= 0.73-0.85, 
p< 0.001) for DBP, and 0.91 (95%CI= 0.84-0.99, p< 0.001) for SBP/DBP. cOnclusiOns: 
The two simple methods of measuring adherence, the single query and VAS, are 
independent predictors of blood pressure control. These measures can be integrated 
seamlessly into routine clinical practice. These findings must be validated in other 
health conditions and therapeutic areas.
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Objectives: Warfarin is an oral anticoagulant used for the prevention of throm-
bosis, and many adjustments are needed to achieve a therapeutic INR. The dose 
of warfarin is important to establish an association between clinical and safety 
outcomes and the exposure. To evaluate the validity of the weekly dose of warfarin 
as reported by the patient compared to the weekly prescribed dose. MethOds: 
This study was based on an ongoing prospective cohort of new warfarin-users to 
assess the genetic and clinical risks associated with the effectiveness and safety 
of warfarin. Demographic and clinical data were collected from 219 patients who 
began the treatment between May 1st, 2010 and Oct. 31st, 2011 at the Montreal 
Heart Institute. They were followed-up each three months for a year. The primary 
outcome is the concordance between the reported and prescribed weekly dose of 
warfarin. The secondary outcome is the difference between the means of reported 
and prescribed warfarin weekly doses. A t-test and a Pearson correlation are used for 
the secondary outcome and a generalized mixed linear model with repeated meas-
ures is used for the primary outcome. Results: Patients had a mean age of 67.7, 
58.9% were men and 70.3% had atrial fibrillation. No significant difference between 
the means of reported and prescribed warfarin weekly dose (Pearson coefficient = 
0.969). However, we observed that the correlation was weak at 3 months for patients 
in the low dose group and in the high dose group (Pearson coefficient = 0.806 and 
0.829, respectively). Mixed linear model analysis detected no association between 
the covariates and the concordance. cOnclusiOns: This study demonstrates that 
the weekly reported dose correlates well with the prescribed dose patients in a 
prospective cohort study. Furthermore, the effect was similar whether measured 
in new-onset users of warfarin and up to 12 months of use.
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Objectives: Adherence to statin therapy is important for an effective reduction 
in cardiovascular events. We aimed to assess the effect of the occurrence of a first 
cardiovascular event on adherence rates in type 2 diabetes patients using a matched 
cohort design. MethOds: A matched cohort study was performed within the IADB.
nl pharmacy database among type 2 diabetes patients, who initiated statin treat-
ment for primary prevention. Index patients experienced a first event (index date) 
after initiation whereas reference patients did not. Index and reference patients 
were matched on gender, age at statin initiation, statin initiation date, adherence 
level before the index date and follow-up period. Adherence was measured as per-
centages of days covered and classified into: non-adherent, partial-adherent or 
full-adherent. Adherence rates were measured from statin initiation until the index 
date, and from the index date until end of follow-up, for reference patients in both 
cases the same follow-up period was used. Mean adherence rates between index 
and reference before and after were compared by the use of an independent samples 
service evaluation of patients undergoing TAVI or AVR between January 2011 and 
May 2012 captured data until 6-months post-procedure, collected from hospital 
records and via a General Practitioner questionnaire. The main endpoints were 
mortality, hospital length of stay (LoS), discharge destination, readmission and 
post-discharge resource use. Subgroup analyses were performed for AVR patients 
aged ≥ 80 (AVR≥ 80) and with Euroscore of ≥ 10 (AVR≥ 10). Results: Results given as 
means (standard deviation) for TAVI (n= 51), AVR (n= 188), AVR≥ 80 (n= 48) and AVR≥ 10 
(n= 47) respectively, unless otherwise stated. Age in years was 83 (3.06), 71 (13.11), 84 
(2.72), 79 (7.12), Logistic Euroscore1 was 24.74 (11.90), 8.07 (6.44), 12.01 (6.04), 16.45 
(6.58) and post-operative LoS in days was 11.51 (11.16), 10.88 (10.82), 14.31 (16.66), 
15.19 (17.67). For patients discharged alive, 0 of 48 (0%), 13 of 180 (7%), 6 of 46 (13%) 
and 4 of 44 (9%), had an unplanned cardiac-related readmission within 30-days of 
discharge. Time to readmission was 74.6 (52.9), 31.1 (37.2), 15.4 (10.5) and 16.7 (12.8) 
days. cOnclusiOns: Despite TAVI being performed in an older, higher risk popula-
tion the LoS is similar to AVR. Most strikingly there were no cardiac-related readmis-
sions within 30-days for TAVI and time to first readmission was significantly longer. 
This evaluation suggests that TAVI is clinically appropriate and provides economic 
advantages in both the hospital and post discharge setting in this high risk group. 
Many patients undergoing TAVI are considered unfit for surgery and hence TAVI 
offers a treatment that delivers similar results to traditional AVR surgery without 
the high risk associated with surgery.
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Objectives: To examine patients’ stated preferences for persisting with medications 
using a discrete choice experiment (DCE) and to explore the relationship with clinical, 
demographic and psycho-social variables. MethOds: A 4-attribute DCE (mild side-
effects, potentially life-threatening but rare side-effects, dose frequency, treatment 
benefits) with 3-levels identified from literature and expert opinion was developed 
using a fractional factorial design. Scenarios were folded into nine forced binary 
choices: Which medicine would you be most likely to continue taking? The survey was 
translated, piloted and approved for eleven European countries. Target sample was 
100≤ n≤ 323 patients prescribed anti-hypertensives per country, recruited by posters 
in community pharmacies or general practices. Results were analysed in STATA using 
a random effects logit model. Results: A total of 2856 patients from Austria (n= 323), 
Belgium (n= 180), England (n= 323), Germany (n= 265), Greece (n= 289), Hungary (n= 323), 
The Netherlands (n= 237), Poland (n= 323) and Wales (n= 323) completed the online 
questionnaire. All four attributes influenced persistence with treatment (p< 0.01). 
Patients were willing to forego chance of improvements in treatment benefits (%) 
in order to improve other attributes: -36.10% (95% CI: -41.24 to -32.94) for a very rare 
risk of life-threatening side-effects; -18.66% (95% CI: -21.51 to -16.67) for once daily 
dose frequency; -0.74% (95% CI: -0.85 to -0.67) to reduce the risk of mild ADR by 1%. 
Likelihood ratio tests showed that models controlling for clinical, demographic and 
psycho-social variables were significantly different from the base-case. There was 
limited evidence that self-reported adherence influenced stated preferences to per-
sist. cOnclusiOns: Patients were willing to trade potential benefits, harms, and 
convenience in responding that they would persist with treatment. Clinical, demo-
graphic and psycho-social factors influence the extent of the trade-offs between 
these attributes. Persistence may therefore be enhanced directly, through selection 
of medicines meeting preferred levels of attributes, or indirectly through targeting 
modifiable psycho-social factors that affect trade-off choices.
PCV117
illuSTraTion of The ComBined effeCT of PaTienT’S adherenCe and 
indiVidual BiologiCal CharaCTeriSTiCS on Blood PreSSure
Tousset E.1, Lowy A.2, Ong S.H.2, Vrijens B.1
1MWV Healthcare, Visé, Belgium, 2Novartis Pharma AG, Basel, Switzerland
Objectives: With the recognition that adherence is commonly imperfect, even with 
once daily regimen, ‘forgiveness’ is becoming acknowledged as an important char-
acteristic in predicting real-world effectiveness. Forgiveness is typically reported 
as a group average value, ignoring person-to-person variability. Here we illustrate 
an alternative way of estimating and presenting information on drug forgiveness 
which allows the estimation of the combined effect of imperfect adherence and 
variable forgiveness. MethOds: Adherence data from 4783 patients with hyper-
tension were used in these simulations. A projected dosing history over 365 days 
was obtained from each of these individual adherence profiles. Longitudinal clinic 
systolic blood pressure (SBP) collected from 4879 patients after drug withdrawal 
were analysed using non linear mixed effect models, allowing the estimation of the 
between-patient variability in the loss of effect (the ‘offset’). Projected SBP profiles 
were obtained by combining each dosing history with 100 offset curves randomly 
sampled from the variance-covariance matrix estimated in the previous step. 
Re-samplings were performed in the resulting dataset using two adherence distri-
butions described in the literature to estimate the proportion of time patients who 
achieved the maximal effect on SBP over a treatment period of 365 days. Results: 
In the first population, 90% of the patients achieved the maximal effect during 95% 
of the time, whereas, in the population presenting a lower adherence, about 80 % 
maintained the maximal effect during 95% of the time. cOnclusiOns: The impact 
imperfect adherence on response is mitigated by drug forgiveness. This methodol-
ogy reveals the person-to-person variability in clinical effectiveness which is hidden 
when forgiveness is considered as a group-average quantity, and shows that the 
agent studied provides a reliable clinical effectiveness despite imperfect adherence. 
Ultimately, this approach could be used to compare drugs with different levels of 
forgiveness and/or regimens in the presence of non-adherence.
